Biogen Owes Patent Royalties For MS Drug, Genentech Says

Biogen Owes Patent Royalties For MS Drug, Genentech Says

Source Node: 1987341
By Lauren Berg (March 1, 2023, 11:02 PM EST) — Biogen Inc. has broken a licensing agreement with Roche Holding AG subsidiary Genentech Inc. by refusing to pay any more royalties from sales of its immunosuppressive drug Tysabri for the treatment of multiple sclerosis and Crohn’s disease, according to a lawsuit filed Tuesday in California federal court….

Time Stamp:

More from Law 360